BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
13 janv. 2025 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 M
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
08 janv. 2025 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology
BioStem Technologies CEO to Present at Biotech Showcase 2025
02 janv. 2025 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies CEO to Present at Biotech Showcase 2025
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
25 nov. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
20 nov. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
12 nov. 2024 07h29 HE
|
BioStem Technologies, Inc.
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
29 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All MAC Regions
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
28 oct. 2024 13h58 HE
|
BioStem Technologies, Inc.
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
17 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
15 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions